Epidemiology and Prognosis of Brain Metastases

Overview

Journal Surg Neurol Int

Specialty Neurology

Date 2013 May 30

PMID 23717790

Citations 91

Authors

Keith J Stelzer

Affiliations

Soon will be listed here.

Abstract

A substantial, but uncertain, number of patients with cancer develop brain metastases. Risk of brain metastasis is recognized to vary with type of primary cancer. Within specific types of primary cancer, prognostic factors for development of brain metastases are being recognized. Recent data suggest that molecular biomarkers that relate to cellular function can predict risk of developing brain metastases. Such information could optimize surveillance standards and/or be used to select patients for preventive interventions. Though average survival for patients with brain metastases is typically less than 6 months, it is well-recognized that subgroups of patients have significant probability of longer survival. Multiple prognostic models have been proposed, validated, and compared without clearly demonstrating superiority of one model over another. However, some factors show consistency as predictive variables across models, and performance status is almost universally significant. Application of predictive models to specific treatments has been difficult. Tumor-specific prognostic models are evolving, and combinations of biological and clinical factors may be used to optimize models for particular primary tumor types.

Citing Articles

Cerebellar re-irradiation after whole brain radiotherapy significant symptom relief with minimal toxicity in metastatic brain patients.

Haisraely O, Jaffe M, Lawerence Y, Talianksy A, Taliansky A Sci Rep. 2025; 15(1):4078.

PMID: 39900974 PMC: 11791060. DOI: 10.1038/s41598-025-88652-7.

Improved detection of brain metastases using contrast-enhanced 3D black-blood TSE sequences compared to post-contrast 3D T1 GRE: a comparative study on 1.5-T MRI.

Chen Zhou Z, Salvador Alvarez E, Hilario A, Cardenas Del Carre A, Romero Coronado J, Lechuga C Eur Radiol. 2025; .

PMID: 39841203 DOI: 10.1007/s00330-025-11363-0.

Utilizing machine-learning techniques on MRI radiomics to identify primary tumors in brain metastases.

Yang W, Su X, Li S, Zhao K, Yue Q Front Neurol. 2025; 15():1474461.

PMID: 39835148 PMC: 11743164. DOI: 10.3389/fneur.2024.1474461.

Role of memantine to mitigate radiation-induced cognitive dysfunction in brain metastasis patient receiving whole brain radiotherapy: a systematic review.

Oktavianda Y, Permata T Radiat Oncol J. 2025; 42(4):281-294.

PMID: 39748529 PMC: 11701468. DOI: 10.3857/roj.2024.00269.

Immunogenomics and spatial proteomic mapping highlight distinct neuro-immune architectures in melanoma vs. non-melanoma-derived brain metastasis.

Mendoza-Valderrey A, Dettmann E, Hanes D, Kessler D, Danilova L, Rau K BJC Rep. 2024; 2(1):38.

PMID: 39516255 PMC: 11524107. DOI: 10.1038/s44276-024-00060-y.

References

Chiou S . Validity of the graded prognostic assessment-derived index to predict brain-metastatic patients' survival after Gamma Knife radiosurgery. Int J Radiat Oncol Biol Phys. 2010; 78(4):1156-62. DOI: 10.1016/j.ijrobp.2009.09.028. View

Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T . Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997; 37(4):745-51. DOI: 10.1016/s0360-3016(96)00619-0. View

Bedikian A, Wei C, Detry M, Kim K, Papadopoulos N, Hwu W . Predictive factors for the development of brain metastasis in advanced unresectable metastatic melanoma. Am J Clin Oncol. 2010; 34(6):603-10. DOI: 10.1097/COC.0b013e3181f9456a. View

Bajard A, Westeel V, Dubiez A, Jacoulet P, Pernet D, Dalphin J . Multivariate analysis of factors predictive of brain metastases in localised non-small cell lung carcinoma. Lung Cancer. 2004; 45(3):317-23. DOI: 10.1016/j.lungcan.2004.01.025. View

. Patterns of failure in patients with resected stage I and II non-small-cell carcinoma of the lung. The Ludwig Lung Cancer Study Group. Ann Surg. 1987; 205(1):67-71. PMC: 1492883. DOI: 10.1097/00000658-198701000-00012. View

Fox B, Cheung V, Patel A, Suki D, Rao G . Epidemiology of metastatic brain tumors. Neurosurg Clin N Am. 2010; 22(1):1-6, v. DOI: 10.1016/j.nec.2010.08.007. View

Berghoff A, Bago-Horvath Z, de Vries C, Dubsky P, Pluschnig U, Rudas M . Brain metastases free survival differs between breast cancer subtypes. Br J Cancer. 2012; 106(3):440-6. PMC: 3273356. DOI: 10.1038/bjc.2011.597. View

Tendulkar R, Liu S, Barnett G, Vogelbaum M, Toms S, Jin T . RPA classification has prognostic significance for surgically resected single brain metastasis. Int J Radiat Oncol Biol Phys. 2006; 66(3):810-7. DOI: 10.1016/j.ijrobp.2006.06.003. View

Eichler A, Kahle K, Wang D, Joshi V, Willers H, Engelman J . EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro Oncol. 2010; 12(11):1193-9. PMC: 3098020. DOI: 10.1093/neuonc/noq076. View

10.

Barnholtz-Sloan J, Yu C, Sloan A, Vengoechea J, Wang M, Dignam J . A nomogram for individualized estimation of survival among patients with brain metastasis. Neuro Oncol. 2012; 14(7):910-8. PMC: 3379797. DOI: 10.1093/neuonc/nos087. View

11.

Nieder C, Nestle U, Motaref B, Walter K, Niewald M, Schnabel K . Prognostic factors in brain metastases: should patients be selected for aggressive treatment according to recursive partitioning analysis (RPA) classes?. Int J Radiat Oncol Biol Phys. 2000; 46(2):297-302. DOI: 10.1016/s0360-3016(99)00416-2. View

12.

Auperin A, Arriagada R, Pignon J, Le Pechoux C, Gregor A, Stephens R . Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999; 341(7):476-84. DOI: 10.1056/NEJM199908123410703. View

13.

Slotman B, Faivre-Finn C, Kramer G, Rankin E, Snee M, Hatton M . Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007; 357(7):664-72. DOI: 10.1056/NEJMoa071780. View

14.

Rades D, Dziggel L, Haatanen T, Veninga T, Lohynska R, Dunst J . Scoring systems to estimate intracerebral control and survival rates of patients irradiated for brain metastases. Int J Radiat Oncol Biol Phys. 2010; 80(4):1122-7. DOI: 10.1016/j.ijrobp.2010.03.031. View

15.

Liew D, Kano H, Kondziolka D, Mathieu D, Niranjan A, Flickinger J . Outcome predictors of Gamma Knife surgery for melanoma brain metastases. Clinical article. J Neurosurg. 2010; 114(3):769-79. DOI: 10.3171/2010.5.JNS1014. View

16.

Lagerwaard F, Levendag P, Nowak P, Eijkenboom W, Hanssens P, Schmitz P . Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys. 1999; 43(4):795-803. DOI: 10.1016/s0360-3016(98)00442-8. View

17.

Smedby K, Brandt L, Backlund M, Blomqvist P . Brain metastases admissions in Sweden between 1987 and 2006. Br J Cancer. 2009; 101(11):1919-24. PMC: 2788258. DOI: 10.1038/sj.bjc.6605373. View

18.

Meyners T, Heisterkamp C, Kueter J, Veninga T, Stalpers L, Schild S . Prognostic factors for outcomes after whole-brain irradiation of brain metastases from relatively radioresistant tumors: a retrospective analysis. BMC Cancer. 2010; 10:582. PMC: 2988027. DOI: 10.1186/1471-2407-10-582. View

19.

Sperduto P, Berkey B, Gaspar L, Mehta M, Curran W . A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys. 2007; 70(2):510-4. DOI: 10.1016/j.ijrobp.2007.06.074. View

20.

Stark A, Stohring C, Hedderich J, Held-Feindt J, Mehdorn H . Surgical treatment for brain metastases: Prognostic factors and survival in 309 patients with regard to patient age. J Clin Neurosci. 2010; 18(1):34-8. DOI: 10.1016/j.jocn.2010.03.046. View